Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Bendstrup (Aarhus, Denmark), F. Bonella (Essen , Germany), E. Bargagli (Siena , Italy), W. Stansen (Ingelheim am Rhein , Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Orsatti (Ingelheim am Rhein, Germany), I. Glaspole (Melbourne, Victoria, Australia). Efficacy and safety of nintedanib in the elderly patient with IPF. 1353

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Concomitant medications and efficacy of nintedanib in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Efficacy and tolerability of ciclesonide (CIC) in the treatment of 24,037 asthmatic patients in routine clinical care Source: Annual Congress 2010 - Pharmacological treatment in primary care Year: 2010 Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018 Year: 2018 Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006 Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Doxofylline: Efficacy and safety in complex treatment of COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Efficacy and safety of bronchoscopy in the elderly Source: Eur Respir J 2004; 24: Suppl. 48, 70s Year: 2004 Safety profile of tiotropium add-on therapy in paediatric patients by gender Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The effectiveness and safety of pre-hospital nebulizer therapy of elderly patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 503s Year: 2002 Once-daily QVA149 has a good safety profile in patients with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010